Sleep Medicine Names in India: A Clinical Reference
The drug classes behind common sleep medicine names prescribed in India, their regulatory status, and the evidence on each class's safety profile.
This reference covers what class each common sleep-medicine name belongs to, what the evidence shows about each class, India's prescription-control status for these drugs, and what that means for hospital pharmacy stocking.
What drug classes do common sleep medicine names in India fall into?
Benzodiazepines (a class that includes diazepam, alprazolam, clonazepam and lorazepam) and Z-drugs (zolpidem, zopiclone, eszopiclone) are the two most commonly prescribed hypnotic classes in India. Both act on the same GABA receptor system despite differing chemical structures. Zolpidem is structurally unrelated to benzodiazepines but binds the same benzodiazepine receptor site, which is why it shares much of their sedative pharmacology.
Melatonin receptor agonists (melatonin itself, and internationally ramelteon) work through an entirely different mechanism. They mimic the body's own sleep-wake signalling hormone rather than depressing the central nervous system. Certain sedating antidepressants, doxepin among them, are also used off-label for insomnia at low doses. Newer orexin-receptor antagonists form a more recently developed class targeting the wake-promoting system directly.
What does the evidence say about Z-drugs versus benzodiazepines?
Z-drugs have robust short-term trial data supporting efficacy for chronic insomnia. They perform similarly to or better than placebo and other options in short-term studies, with a generally favourable near-term safety profile. Longer-term observational data tells a different story: Z-drugs significantly increased the risk of falls and fractures compared with no treatment or melatonin agonists.
A network meta-analysis of pharmacological treatments for insomnia found eszopiclone and lemborexant showing a favourable overall profile among longer-term options. Eszopiclone carried a meaningfully higher rate of adverse events, and safety data on lemborexant were described as inconclusive at the time of review. Melatonin and ramelteon, by contrast, did not show material benefit over placebo in the same analysis, despite a more favourable dependence profile.
Are benzodiazepines still the right first-line choice for insomnia?
Clinical guidance increasingly favours reserving benzodiazepines and Z-drugs for second-line use, behind melatonin agonists and low-dose sedating antidepressants like doxepin, particularly in older adults. This follows from the accumulated fall and fracture risk data. One guideline framework specifically recommends controlled-release melatonin and doxepin as first-line agents in older adults, with Z-drugs held back for cases where first-line options prove ineffective.
India's own prescribing pattern, where benzodiazepines outnumbered zolpidem nearly three to one in observational data, suggests actual practice has not yet caught up with this shift in guideline preference, which is a gap worth naming directly rather than assuming guideline and practice move together.
What is the regulatory status of these sleep medicine names in India?
Benzodiazepines and related hypnotics in India sit under controls linked to the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, layered on top of standard Schedule H prescription requirements under the Drugs and Cosmetics Rules, 1945. Sale without a valid prescription from a registered medical practitioner is not permitted, and record-keeping obligations at the pharmacy level are stricter than for a typical Schedule H drug.
This dual layer of control, ordinary prescription-only status plus psychotropic-substance handling requirements, is specifically why hospital pharmacies need documented dispensing and storage protocols for this category rather than treating it like a standard prescription medicine shelf.
How should a hospital pharmacy think about stocking sleep medicine names?
A hospital pharmacy formulary for insomnia should reflect the clinical-guideline shift toward melatonin agonists and low-dose sedating antidepressants as earlier options, while still reliably stocking benzodiazepines and Z-drugs given how commonly they're actually prescribed in India today. Getting this stocking mix wrong in either direction, running out of a first-line option or over-relying on higher-risk benzodiazepines, has real downstream consequences for patients, particularly older inpatients at elevated fall risk.
When a hospital's own pharmacy can't reliably supply the specific sleep medicine a psychiatrist or physician has prescribed, subject to the NDPS-linked controls this category carries, a patient's prescription often has to be filled at an external chemist, which breaks both continuity of care and the additional record-keeping oversight a hospital pharmacy is positioned to provide for controlled substances. A managed or in-house hospital pharmacy that stocks this category reliably, with the documentation controls it requires, keeps that prescription and its oversight inside the hospital. Medyzen's guides on managed hospital pharmacy services and prescription leakage and hospital revenue loss cover this stocking and continuity problem in more depth, and the Schedule H, H1 and X drugs guide covers the documentation obligations controlled categories like this one carry.
Sources
- 1Effects of sedative-hypnotics on sleep quality among patients with insomnia: evidence from an observational, pre-post study in India — PMC, National Institutes of Health
- 2Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis — The Lancet
- 3Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review — PMC, National Institutes of Health
- 4Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports — PMC, National Institutes of Health
- 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Rules, 1945 — CDSCO, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Sleep medicine selection and dosing should be individualised by a qualified physician; these are controlled substances requiring a valid prescription in India.
FAQ
Frequently asked questions
The main classes are benzodiazepines (diazepam, alprazolam, clonazepam, lorazepam), Z-drugs (zolpidem, zopiclone, eszopiclone), melatonin receptor agonists, sedating antidepressants like low-dose doxepin, and newer orexin-receptor antagonists, each working through a different pharmacological mechanism.
Z-drugs show a comparable short-term efficacy and safety profile to benzodiazepines in interventional studies, but longer-term observational data shows both classes significantly increasing fall and fracture risk compared with melatonin agonists, which is why clinical guidance increasingly favours melatonin-based options as an earlier step for older patients specifically.
Yes. Benzodiazepines and related hypnotics fall under controls linked to the NDPS Act, 1985, layered on top of Schedule H prescription requirements under the Drugs and Cosmetics Rules, 1945, meaning stricter record-keeping and dispensing controls apply compared with a standard prescription medicine.
Evidence on melatonin's overall benefit is mixed; a comparative network meta-analysis found melatonin and ramelteon not showing material overall benefit over placebo, even though melatonin's dependence and withdrawal profile is considerably more favourable than benzodiazepines or Z-drugs.
An Indian observational study found benzodiazepines prescribed in 73.7% of studied patients compared with 26.3% for zolpidem, even though physicians in the same study rated zolpidem as safer, suggesting prescribing habit and guideline-preferred practice have not yet converged in routine Indian clinical settings.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.